Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
about
Time-dependent endpoints as predictors of overall survival in multiple myelomaTherapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
P2860
Q30538040-264D83E3-6C5F-49D0-B438-2C0FD9613844Q33710118-D6593C93-7B1F-4BEB-8193-F29CB7A8CBB2Q35541950-8BB7F76E-A9FA-402A-BBD4-A243BF637124Q36349459-F14F98CB-7C61-418F-8C23-BEA6EB7F2AC9Q38259501-4A4B3C93-4CBE-43EF-87CC-D1E673765B05Q38830206-21D4F4AD-CEFC-43CF-9621-59F9856EB3DCQ39067386-7F0C8FD3-22DB-46C4-A602-B6F17803908FQ43518078-A304621C-25FA-412A-B098-C8E0C7AC3ED6Q43870660-28AE962F-39E4-40A4-AA68-BE55126BD188Q47178340-DADEFC90-69FB-4A5A-AF05-FCD42A2D6C64Q54542682-E4CDC9A2-8F0B-4E1C-A89B-BD21839174AF
P2860
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Progression-free survival and ...... lysis of 36 randomized trials.
@en
Progression-free survival and ...... lysis of 36 randomized trials.
@nl
type
label
Progression-free survival and ...... lysis of 36 randomized trials.
@en
Progression-free survival and ...... lysis of 36 randomized trials.
@nl
prefLabel
Progression-free survival and ...... lysis of 36 randomized trials.
@en
Progression-free survival and ...... lysis of 36 randomized trials.
@nl
P2093
P2860
P1476
Progression-free survival and ...... lysis of 36 randomized trials.
@en
P2093
Daisuke Takahari
Junko Ikeda
Kohei Shitara
Takashi Ura
Tomoya Yokota
P2860
P2888
P304
P356
10.1007/S10637-011-9648-Y
P577
2011-02-25T00:00:00Z